- Home
- SNBR vs ALMS Comparison
SNBR vs ALMS Comparison
Compare SNBR & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNBR
- ALMS
- Stock Information
- Founded
- SNBR 1987
- ALMS 2021
- Country
- SNBR United States
- ALMS United States
- Employees
- SNBR N/A
- ALMS N/A
- Industry
- SNBR Home Furnishings
- ALMS
- Sector
- SNBR Consumer Discretionary
- ALMS
- Exchange
- SNBR Nasdaq
- ALMS NYSE
- Market Cap
- SNBR 399.8M
- ALMS 402.6M
- IPO Year
- SNBR 1998
- ALMS 2024
- Fundamental
- Price
- SNBR $9.02
- ALMS $4.46
- Analyst Decision
- SNBR Hold
- ALMS Strong Buy
- Analyst Count
- SNBR 2
- ALMS 7
- Target Price
- SNBR $9.00
- ALMS $28.00
- AVG Volume (30 Days)
- SNBR 790.4K
- ALMS 410.3K
- Earning Date
- SNBR 04-30-2025
- ALMS 05-19-2025
- Dividend Yield
- SNBR N/A
- ALMS N/A
- EPS Growth
- SNBR N/A
- ALMS N/A
- EPS
- SNBR N/A
- ALMS N/A
- Revenue
- SNBR $1,605,108,000.00
- ALMS N/A
- Revenue This Year
- SNBR N/A
- ALMS N/A
- Revenue Next Year
- SNBR $4.19
- ALMS N/A
- P/E Ratio
- SNBR N/A
- ALMS N/A
- Revenue Growth
- SNBR N/A
- ALMS N/A
- 52 Week Low
- SNBR $4.48
- ALMS $3.18
- 52 Week High
- SNBR $20.75
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- SNBR 68.21
- ALMS N/A
- Support Level
- SNBR $6.63
- ALMS N/A
- Resistance Level
- SNBR $8.61
- ALMS N/A
- Average True Range (ATR)
- SNBR 0.64
- ALMS 0.00
- MACD
- SNBR 0.32
- ALMS 0.00
- Stochastic Oscillator
- SNBR 96.61
- ALMS 0.00
About SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.